Some big news about tiny molecules: cc-TDI has recently been awarded an AIMS Award from Atomwise to create a molecularly-designed new drug for EWSR1 fusion sarcomas of children and adults. Relevant cancers include difficult-to-treat diseases such as Ewing’s Sarcoma, Clear Cell Sarcoma and Sclerosing Epithelioid Fibrosarcoma. The intent is to create a small molecule that interferes with the central driving gene of these sarcomas, hopefully leading to an effective new treatment.

Share this post
Share on facebook
Share on google
Share on twitter
Share on linkedin